Effexor (Major Depressive Disorder) – Forecast and Market Analysis to 2023

Pages: 45 Published: May 01, 2014 Report Code: GDHC417DFR

Major depressive disorder (MDD) is one of the most common psychiatric diseases worldwide. The MDD market is a crowded and competitive market, with more than 30 marketed products available for the treatment of patients with MDD. The depression market is about to enter a dynamic phase with imminent patent expiries for top selling products, such as Eli Lilly’s Cymbalta, and Otsuka/BMS’s Abilify, along with the recent launch of the multimodal antidepressant, Lundbeck/Takeda’s Brintellix, in January 2014, and the potential introduction of seven promising late-stage pipeline products into the market during the forecast period, from 2013 to 2023. Effexor (venlafaxine) is an antidepressant that belongs to the SNRI class. It was developed and launched by Wyeth, which was later fully acquired by Pfizer. Effexor first became available in the US and 5EU in 1994, and its extended release formulation (Effexor XR) was introduced into the US and 5EU markets in 1998.

Scope

Overview of Major depressive disorder, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.

Detailed information on Effexor including product description, safety and efficacy profiles as well as a SWOT analysis.

Sales forecast for Effexor for the top seven countries from 2013 to 2023.

Sales information covered for the US, France, Germany, Italy, Spain, the UK and Australia.

Reasons to Buy

Understand and capitalize by identifying products that are most likely to ensure a robust return

Stay ahead of the competition by understanding the changing competitive landscape for Major depressive disorder

Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential

Make more informed business decisions from insightful and in-depth analysis of Effexor performance

Obtain sales forecast for Effexor from 2013-2023 in the top seven countries (the US, France, Germany, Italy, Spain, the UK and Australia)

Table of Contents

1Table of Contents1

1.1List of Tables3

1.2List of Figures4

2Executive SUmmary4

2.1Sales for Effexor in the Major Depressive Disorder (MDD) Market5

2.2What Do the Physicians Think?6

3Introduction8

3.1Catalyst8

3.2Related Reports9

3.3Upcoming Related Reports10

4Disease Overview11

4.1Etiology and Pathophysiology11

4.1.1Etiology11

4.1.2Pathophysiology11

4.2Classification13

4.3Symptoms and Subtypes of Major Depressive Disorder15

4.4Prognosis16

4.5Quality of Life16

5Disease Management16

5.1Diagnosis and Treatment Overview16

5.1.1Diagnosis16

5.1.2Treatment Guidelines and Leading Prescribed Drugs18

5.1.3Clinical Practice21

6Competitive Assessment25

6.1Overview25

7Effexor (Venlafaxine)28

7.1Overview28

7.2Efficacy29

7.3Safety30

7.4SWOT Analysis31

7.5Forecast31

8Appendix32

8.1Bibliography32

8.2Abbreviations35

8.3Methodology37

8.4Forecasting Methodology37

8.4.1Diagnosed MDD Patients37

8.4.2Percent of Drug-Treated Patients37

8.4.3General Pricing Assumptions38

8.4.4Individual Drug Assumptions38

8.4.5Generic Erosion39

8.5Physicians and Specialists Included in this Study40

8.6About the Authors42

8.6.1Analyst42

8.6.2Therapy Area Directors42

8.6.3Global Head of Healthcare43

8.7About GlobalData44

8.8Contact Us44

8.9Disclaimer44

List of Tables

Table 1: Effexor: Key Metrics in the 7MM and Australia Major Depressive Disorder Markets, 2013–20234

Table 2: Classification and Criteria of Major Depressive Disorder (DSM-IV) and Major Depressive Episode (ICD-10)14

Table 3: Subtypes of Major Depressive Disorder15

Table 4: Severity of Depressive Episodes according to ICD-10 and DSM-IV Diagnostic Criteria17

Table 5: Treatment Guidelines for Major Depressive Disorder19

Table 6: Most Prescribed Drugs for MDD by Class in the 7MM and Australia, 201321

Table 7: Leading Treatments for MDD, 201327

Table 8: Product Profile – Effexor29

Table 9: Effexor SWOT Analysis, 201431

Table 10:Global MDD Sales Forecasts ($m) for Effexor XR, 2013–202332

Table 11:High-Prescribing Physicians (Non-KOLs) Surveyed, by Country41

List of Figures

Figure 1: Sales for Effexor by Region, 2013-20236

Figure 2: Overview of Targets of Antidepressant Action on Noradrenergic and Serotonergic Neurons13

Figure 3: Disease Management Model for Major Depressive Disorder23

Figure 4: Major Depressive Disorder Treatment Algorithm25

$3,495

Can be used by individual purchaser only

$10,485

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Get in touch to find out about our multi-purchase discounts

reportstore@globaldata.com
Tel +44 (0) 20 7947 2960

Every customer’s requirement is unique. We understand that and can customize the report basis your exact research requirements pertaining to market insights, innovation insights, strategy and planning, and competitive intelligence. You can also avail the option of purchasing stand-alone sections of the report or request for a country specific report.

GDPR + CCPA Compliant

Personal and transaction information are kept safe from unauthorised use.

Recently Viewed Reports

Testimonial

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods
Looking to stay on top of industry & market trends?

Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.

Central Nervous System
New
Diabetic Foot Ulcers Market Size, Share and Trends Analysis by…
$3,950 | November 2022
Central Nervous System
New
Dry Eye Syndrome Market Size, Share and Trends Analysis by…
$3,950 | November 2022
Central Nervous System
New
Non-Small Cell Lung Cancer Marketed and Pipeline Drugs Assessment, Clinical…
$3,495 | November 2022